GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » Short-Term Debt

AP Biosciences (ROCO:6945) Short-Term Debt : NT$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is AP Biosciences Short-Term Debt?

AP Biosciences's Short-Term Debt for the quarter that ended in Dec. 2024 was NT$0.00 Mil.

AP Biosciences Short-Term Debt Historical Data

The historical data trend for AP Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AP Biosciences Short-Term Debt Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
- - - - -

AP Biosciences Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Short-Term Debt Get a 7-Day Free Trial - - - - -

AP Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

AP Biosciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of AP Biosciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AP Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » Short-Term Debt
Comparable Companies
TPE:6794 ROCO:1777 ROCO:3176 ROCO:6808 TPE:6838 ROCO:6986 ROCO:8279 ROCO:06891 ROCO:6733 ROCO:6864 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 17th Floor, Taipei, TWN
Website
https://www.apbioinc.com
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.

AP Biosciences Headlines

No Headlines